ABILITY BCI

ABILITY BCI

ABILITY Neurotech has developed a next generation, fully implantable BCI system spun out of the Wyss Center for Bio and Neuroengineering in Geneva after more than 8 years of R&D and approximately $50M in investment. The core innovation is a laser based transcutaneous optical data link that achieves 50 Mb/s lossless neural data transmission, representing orders of magnitude beyond existing wireless BCI approaches, while requiring no battery implant and no percutaneous wires.

The implant captures broadband neural signals from cortical electrodes and transmits them through intact skin to an external processor, which performs real time AI decoding to reconstruct intended speech or movement.

Key technical specifications validated in bench testing and pre clinical work include:

  • Latency: 2 ms end to end
  • Data loss: less than 1 sample per million
  • Dynamic range: ±6 mV
  • Resolution: 0.18 µV

ABILITY is now entering active clinical execution. Intraoperative studies are approved and underway in Munich at LMU and TUM, and the INTRECOM First in Human chronic implant study, which is NCT registered, is on track for Q3 2026 at UMC Utrecht and the Medical University of Graz. The company holds FDA Breakthrough Device Designation pending and is pursuing parallel EU MDR and FDA regulatory pathways.

The Summit demo will showcase the full system, including the implantable device, optical transceiver unit, and real time neural decoding pipeline, demonstrating live signal acquisition and AI based decoding relevant to restoring communication in paralyzed patients.

The demo directly addresses the global health challenge of motor and communication disability, which affects hundreds of millions of people worldwide.

 

Share this speaker
Share This Speaker
  • Organization
    ABILITY Neurotech
  • Profession
    Fully implantable optical brain-computer interface restoring communication and motor function for neurological patients

Are you sure you want to remove this speaker?